Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of rezafungin vs caspofungin for candidemia/invasive candidiasis
CTR20192399Phase 3Completed
- Sponsor
- Almac Group
- Start
- Dec 2019
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rezafungin in candidemia, invasive candidiasis, sponsored by Almac Group. Started Dec 2019; status: completed.
02
Drugs
rezafungin
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on CTR20192399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192399.